Phase I trial of elacytarabine + idarubicin in patients with AML.

Trial Profile

Phase I trial of elacytarabine + idarubicin in patients with AML.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2009

At a glance

  • Drugs Elacytarabine (Primary) ; Idarubicin
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Apr 2009 New trial record.
    • 22 Apr 2009 Results were presented at the 100th Annual Meeting of the American Association of Cancer Research (AACR) in Denver, Colorado.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top